Congress Abstracts

  • (Levrat-Guillen et al., EPV172 / #635). This retrospective cohort analysis showed that adults with type 1 diabetes in Sweden reported fewer severe hypoglycemia episodes after switching from real-time continuous glucose monitoring with predictive alarms to intermittently scanned CGM.
  • (Ratzki-Leewing et al, OP050 / #212). Real-world evidence from Ontario demonstrated that in individuals over 65 years old with type 2 diabetes receiving GLP-1 receptor agonists and/or oral therapy, initiation of Freestyle Libre was associated with a significant reduction in HbA1c, while statistically significant improvements in healthcare resource utilization were observed only among those on oral therapy, possibly due to the smaller number of GLP-1 RA users in the study.
  • (Huang & Bindal, EPV202 / #720). This retrospective matched-cohort (CGM users vs no CGM) showed that consistent use of FreeStyle Libre continuous glucose monitoring is associated with significantly lower rates of GLP-1 receptor agonist discontinuation among adults with type 2 diabetes on non-intensive therapy, suggesting improved medication adherence.
  • (Soriano et al., EPV216 / #1303). This randomized controlled trial found that adults with type 2 diabetes (T2D) using FreeStyle Libre 3 showed significantly greater improvements in HbA1c and T2D engagement scores compared to those using traditional blood glucose monitoring.
  • Clinically significant A1C and AG-derived A1C discordance is common, particularly in Black individuals. Personalized A1C addresses this discrepancy potentially improving clinical management in diabetes and reducing health disparities.
  • People with T2DM not using insulin showed large, clinically significant improvements in CGM metrics and HbA1c when using either FSL CGM alone or FSL CGM plus a food logging application.
  • A subgroup analysis of the RELIEF study suggests that use of the FSL is associated with reduced hospital admissions for ADEs in people with T2DM treated with oral insulin-secretagogue drugs without insulin. Results suggest FSL may help support treatment optimization and reduce treatment inertia.
  • Compared to pre-FSL use, patients using FSL with type 2 diabetes treated with SU/meglitinides had lower healthcare utilization. Further research should assess the financial and patient impact of these event reductions.
  • A retrospective cohort study shows that frequent use of FSL plays a pivotal role in glucose management among people with T2D treated with basal insulin and GLP-1 RAs, where consistent FSL use is associated with sustained glycemic control, and inconsistent FSL use is associated with worsened glycemic outcomes.
  • After FreeStyle Libre adoption, HbA1c was statistically significantly improved across age groups, and there was a reduced total healthcare burden related to ED visits and hospitalization rates (overall, for DKA, and for hypoglycemia).
  • From a Canadian private payer perspective, FreeStyle systems are cost effective compared with SMBG for all peopleliving with diabetes.
  • In people with insulin-treated T2DM, initiation of is CGM is associated with reduced HbA1c and reduced relative risk for hospitalization compared with BGM controls
  • In adults with T1DM, initiating is CGM is associated with reduced HbA1c and reduced rates of hospitalization compared with BGM controls
  • There is high similarity between HbA1c and GMI-BG in the DCCT for indication of sustained progression of retinopathy, despite the intermittent but structured 7-point BG measurement

CE/CME Programs